vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v22i6.2666vsp-3354Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWРоль ингибиторов кальциневрина в лечении атопического дерматита у детейRole of Calcineurin Inhibitors in the Management of Atopic Dermatitis in Childrenhttps://orcid.org/0000-0003-0317-2425ЭфендиеваК. Е.EfendievaKamilla E.

Эфендиева Камилла Евгеньевна - кандидат медицинских наук, заместитель руководителя по международным связям и образовательной деятельности, ведущий научный сотрудник, врач аллерголог-иммунолог НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского» Минобрнауки России.

119333, Москва, ул. Фотиевой, д. 10, стр. 1

Тел.: +7 (499) 137-01-97

Moscow

kamillaef@inbox.ruhttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва

Moscow

https://orcid.org/0000-0002-2460-7718ЛевинаЮ. Г.LevinaJuliya G.

Москва

Moscow

https://orcid.org/0000-0002-3781-8661КалугинаВ. Г.KaluginaVera G.

Москва

Moscow

https://orcid.org/0000-0001-5665-7835АлексееваА. А.AlekseevaAnna A.

Москва

Moscow

https://orcid.org/0000-0001-7398-0562ВишневаЕ. А.VishnevaElena A.

Москва

Moscow

https://orcid.org/0000-0002-5844-5075ВолковК. С.VolkovKonstantin S.

Москва

Moscow

НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; РНИМУ им. Н.И. ПироговаРоссияResearch Institute of Pediatrics and Children's Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияResearch Institute of Pediatrics and Children's Health in Petrovsky National Research Centre of SurgeryRussian Federation202311012024226513520Copyright © Эфендиева К.Е., Намазова-Баранова Л.С., Левина Ю.Г., Калугина В.Г., Алексеева А.А., Вишнева Е.А., Волков К.С., 20232023Эфендиева К.Е., Намазова-Баранова Л.С., Левина Ю.Г., Калугина В.Г., Алексеева А.А., Вишнева Е.А., Волков К.С.Efendieva K.E., Namazova-Baranova L.S., Levina J.G., Kalugina V.G., Alekseeva A.A., Vishneva E.A., Volkov K.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3354

Атопический дерматит (АтД) является широко распространенным хроническим воспалительным заболеванием кожи, оказывающим серьезное влияние на различные аспекты жизни пациента. В данной обзорной статье представлен современный взгляд на патофизиологию АтД, его взаимосвязь с другими сопутствующими заболеваниями, а также обсуждены практические аспекты применения наружной противовоспалительной терапии. Проведенный анализ клинических исследований демонстрирует важную роль ингибиторов кальциневрина в эффективном лечении АтД у детей, начиная с первых его проявлений в раннем возрасте.

Atopic dermatitis (AD) is a widespread chronic inflammatory skin disease that has a significant impact on various aspects of patient's life. This review presents modern view on AD pathophysiology, its correlation with other concomitant diseases, and covers practical aspects of external anti-inflammatory therapy implementation. The analysis of clinical studies has shown the significant role of calcineurin inhibitors in the effective treatment of AD in children from its first manifestations at early age.

атопический дерматитдетиингибиторы кальциневринапимекролимусatopic dermatitischildrencalcineurin inhibitorpimecrolimusReferencesАтопический дерматит у детей: клинические рекомендации / Российское общество дерматовенерологов и косметологов; Российская ассоциация аллергологов и клинических иммунологов; Союз педиатров России. — Минздрав России; 2021. — 81 с.Atopicheskii dermatit u detei: Clinical recommendations. Russian Society of Dermatovenerologists and Cosmetologists; Russian Association of Allergists and Clinical Immunologists; Union of Pediatricians of Russia. Ministry of Health of Russia; 2021. 81 p. (In Russ).Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema — part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi: https://doi.org/10.1111/jdv.18429Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema — part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi: https://doi.org/10.1111/jdv.18429Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/S0140-6736(20)31286-1Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/S0140-6736(20)31286-1Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160. doi: https://doi.org/10.2340/00015555-3510Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160. doi: https://doi.org/10.2340/00015555-3510Dogruel D, Bingol G, Altintas DU, et al. Prevalence of and risk factors for atopic dermatitis: a birth cohort study of infants in southeast Turkey. Allergol Immunopathol (Madr). 2016;44(3): 214–220. doi: https://doi.org/10.1016/j.aller.2015.07.002Dogruel D, Bingol G, Altintas DU, et al. Prevalence of and risk factors for atopic dermatitis: a birth cohort study of infants in southeast Turkey. Allergol Immunopathol (Madr). 2016;44(3): 214–220. doi: https://doi.org/10.1016/j.aller.2015.07.002Wartna JB, Moed H, van Alphen EI, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2):143–150. doi: https://doi.org/10.3109/02813432.2016.1160629Wartna JB, Moed H, van Alphen EI, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2):143–150. doi: https://doi.org/10.3109/02813432.2016.1160629Weber A, Herr C, Hendrowarsito L, et al. No further increase in the parent reported prevalence of allergies in Bavarian preschool children: Results from three cross-sectional studies. Int J Hyg Environ Health. 2016;219(4-5):343–348. doi: https://doi.org/10.1016/j.ijheh.2016.02.001Weber A, Herr C, Hendrowarsito L, et al. No further increase in the parent reported prevalence of allergies in Bavarian preschool children: Results from three cross-sectional studies. Int J Hyg Environ Health. 2016;219(4-5):343–348. doi: https://doi.org/10.1016/j.ijheh.2016.02.001Montefort S, Ellul P, Montefort M, et al. Increasing prevalence of asthma, allergic rhinitis but not eczema in 5- to 8-yr-old Maltese children (ISAAC). Pediatr Allergy Immunol. 2009;20(1):67–71. doi: https://doi.org/10.1111/j.1399-3038.2008.00746.xMontefort S, Ellul P, Montefort M, et al. Increasing prevalence of asthma, allergic rhinitis but not eczema in 5- to 8-yr-old Maltese children (ISAAC). Pediatr Allergy Immunol. 2009;20(1):67–71. doi: https://doi.org/10.1111/j.1399-3038.2008.00746.xNapolitano M, Fabbrocini G, Martora F, et al. Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022;35(12):e15901. doi: https://doi.org/10.1111/dth.15901Napolitano M, Fabbrocini G, Martora F, et al. Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022;35(12):e15901. doi: https://doi.org/10.1111/dth.15901Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124(6):1251–1258.e23. doi: https://doi.org/10.1016/j.jaci.2009.10.009Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124(6):1251–1258.e23. doi: https://doi.org/10.1016/j.jaci.2009.10.009Mallol J, Crane J, von Mutius E, et al. The international study of asthma and allergies in childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73–85. doi: https://doi.org/10.1016/j.aller.2012.03.001Mallol J, Crane J, von Mutius E, et al. The international study of asthma and allergies in childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73–85. doi: https://doi.org/10.1016/j.aller.2012.03.001Kleiner A, Flohr C, Weiland S, et al. International variation in prevalence of flexural eczema and atopic sensitization. Results from phase two of the International Study of Asthma and Allergies in Childhood (ISAAC Phase Two). Allergo J. 2008;17(1):79–81.Kleiner A, Flohr C, Weiland S, et al. International variation in prevalence of flexural eczema and atopic sensitization. Results from phase two of the International Study of Asthma and Allergies in Childhood (ISAAC Phase Two). Allergo J. 2008;17(1):79–81.Pesce G, Marcon A, Carosso A, et al. Adult eczema in Italy: prevalence and associations with environmental factors. J Eur Acad Dermatol Venereol. 2015;29(6):1180–1187. doi: https://doi.org/10.1111/jdv.12784Pesce G, Marcon A, Carosso A, et al. Adult eczema in Italy: prevalence and associations with environmental factors. J Eur Acad Dermatol Venereol. 2015;29(6):1180–1187. doi: https://doi.org/10.1111/jdv.12784Theodosiou G, Montgomery S, Metsini A, et al. Burden of atopic dermatitis in Swedish adults: a population-based study. Acta Derm Venereol. 2019;99(11):964–970. doi: https://doi.org/10.2340/00015555-3257Theodosiou G, Montgomery S, Metsini A, et al. Burden of atopic dermatitis in Swedish adults: a population-based study. Acta Derm Venereol. 2019;99(11):964–970. doi: https://doi.org/10.2340/00015555-3257Котова Е.Г., Кобякова О.С., Александрова Г.А. и др. Общая заболеваемость детского населения России (0–14 лет) в 2022 году: статистические материалы. — М.: ЦНИИОИЗ Минздрава России; 2023.Kotova EG, Kobyakova OS, Aleksandrova GA, et al. Obshchaya zabolevaemost’ detskogo naseleniya Rossii (0–14 let) v 2022 godu: statisticheskie materialy. Moscow: Central Research Institute of Organization and Informatization of Health Care of the Ministry of Health of Russian Federation; 2023. (In Russ).Намазова-Баранова Л.С. Аллергия у детей: от теории — к практике. — М.: Союз педиатров России; 2011.Namazova-Baranova LS. Allergiya u detei: ot teorii — k praktike. Moscow: Union of Pediatricians of Russia; 2011. (In Russ).Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537): 733–743. doi: https://doi.org/10.1016/S0140-6736(06)69283-0Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537): 733–743. doi: https://doi.org/10.1016/S0140-6736(06)69283-0Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: https://doi.org/10.1038/s41572-018-0001-zWeidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: https://doi.org/10.1038/s41572-018-0001-zWeidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387:1109–1122. doi: https://doi.org/10.1016/S0140-6736(15)00149-XWeidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387:1109–1122. doi: https://doi.org/10.1016/S0140-6736(15)00149-XTorres T, Ferreira EO, Gonçalo M, et al. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606–613. doi: https://doi.org/10.20344/amp.11963Torres T, Ferreira EO, Gonçalo M, et al. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606–613. doi: https://doi.org/10.20344/amp.11963Apfelbacher CJ, Diepgen TL, Schmitt J. Determinants of eczema: population‐based cross‐sectional study in Germany. Allergy. 2011;66(2):206–213. doi: https://doi.org/10.1111/j.1398-9995.2010.02464.xApfelbacher CJ, Diepgen TL, Schmitt J. Determinants of eczema: population‐based cross‐sectional study in Germany. Allergy. 2011;66(2):206–213. doi: https://doi.org/10.1111/j.1398-9995.2010.02464.xАтопический дерматит у детей: клинические рекомендации / Союз педиатров России; Российская ассоциация аллергологов и клинических иммунологов; Российское общество дермато-венерологов и косметологов. — Минздрав России; 2016. — 60 с.Atopicheskii dermatit u detei: Clinical recommendations. Russian Society of Dermatovenerologists and Cosmetologists; Russian Association of Allergists and Clinical Immunologists; Union of Pediatricians of Russia. Ministry of Health of Russia; 2016. 60 p. (In Russ).Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14): 1315–1327. doi: https://doi.org/10.1056/NEJMra1011040Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14): 1315–1327. doi: https://doi.org/10.1056/NEJMra1011040Juul-Dam M, Sejersen H, Vestergaard C, et al. The impact of filaggrin genotype and atopic dermatitis on risk and severity of keratoconus. J EuCornea. 2020;7:4–7. doi: https://doi.org/10.1016/j.xjec.2020.02.001Juul-Dam M, Sejersen H, Vestergaard C, et al. The impact of filaggrin genotype and atopic dermatitis on risk and severity of keratoconus. J EuCornea. 2020;7:4–7. doi: https://doi.org/10.1016/j.xjec.2020.02.001Paternoster L, Standl M, Waage J, et al. Multi‐ancestry genome‐wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449–1456. doi: https://doi.org/10.1038/ng.3424Paternoster L, Standl M, Waage J, et al. Multi‐ancestry genome‐wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449–1456. doi: https://doi.org/10.1038/ng.3424South AP, Cabral A, Ives JH, et al. Human epidermal differentiation complex in a single 2.5 Mbp long continuum of overlapping DNA cloned in bacteria integrating physical and transcript maps. J Invest Dermatol. 1999;112(6):910–918. doi: https://doi.org/10.1046/j.1523-1747.1999.00613.xSouth AP, Cabral A, Ives JH, et al. Human epidermal differentiation complex in a single 2.5 Mbp long continuum of overlapping DNA cloned in bacteria integrating physical and transcript maps. J Invest Dermatol. 1999;112(6):910–918. doi: https://doi.org/10.1046/j.1523-1747.1999.00613.xStemmler S, Hoffjan S. Trying to understand the genetics of atopic dermatitis. Mol Cell Probes. 2016;30(6):374–385. doi: https://doi.org/10.1016/j.mcp.2016.10.004Stemmler S, Hoffjan S. Trying to understand the genetics of atopic dermatitis. Mol Cell Probes. 2016;30(6):374–385. doi: https://doi.org/10.1016/j.mcp.2016.10.004Halling-Overgaard AS, Kezic S, Jakasa I, et al. Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol. 2017;177(1):84–106. doi: https://doi.org/10.1111/bjd.15065Halling-Overgaard AS, Kezic S, Jakasa I, et al. Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol. 2017;177(1):84–106. doi: https://doi.org/10.1111/bjd.15065Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014;14(5):433. doi: https://doi.org/10.1007/s11882-014-0433-9Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014;14(5):433. doi: https://doi.org/10.1007/s11882-014-0433-9Kamata Y, Tominaga M, Takamori K. Itch in atopic dermatitis management. Curr Probl Dermatol. 2016;50:86–93. doi: https://doi.org/10.1159/000446048Kamata Y, Tominaga M, Takamori K. Itch in atopic dermatitis management. Curr Probl Dermatol. 2016;50:86–93. doi: https://doi.org/10.1159/000446048Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol. 2009;129(8):1878–1891. doi: https://doi.org/10.1038/jid.2009.71Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol. 2009;129(8):1878–1891. doi: https://doi.org/10.1038/jid.2009.71Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017; 140(3):633–643. doi: https://doi.org/10.1016/j.jaci.2017.07.006Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017; 140(3):633–643. doi: https://doi.org/10.1016/j.jaci.2017.07.006Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110. doi: https://doi.org/10.4172/2155-9899.1000110Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110. doi: https://doi.org/10.4172/2155-9899.1000110Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067-1070. doi: https://doi.org/10.1038/jid.2008.88Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067-1070. doi: https://doi.org/10.1038/jid.2008.88Totte JE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687-695. doi: https://doi.org/10.1111/bjd.14566Totte JE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687-695. doi: https://doi.org/10.1111/bjd.14566Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-859. doi: https://doi.org/10.1101/gr.131029.111Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-859. doi: https://doi.org/10.1101/gr.131029.111Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017; 9(378):eaah4680. doi: https://doi.org/10.1126/scitranslmed.aah4680Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017; 9(378):eaah4680. doi: https://doi.org/10.1126/scitranslmed.aah4680Myles IA, Earland NJ, Anderson ED, et al. First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight. 2018;3(9):e120608. doi: https://doi.org/10.1172/jci.insight.120608Myles IA, Earland NJ, Anderson ED, et al. First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight. 2018;3(9):e120608. doi: https://doi.org/10.1172/jci.insight.120608Siegels D, Haufe E, Heinrich L, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021;5: 274-286. doi: https://doi.org/10.5414/ALX02262ESiegels D, Haufe E, Heinrich L, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021;5: 274-286. doi: https://doi.org/10.5414/ALX02262EIlli S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925-931. doi: https://doi.org/10.1016/j.jaci.2004.01.778Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925-931. doi: https://doi.org/10.1016/j.jaci.2004.01.778von Kobyletzki LB, Bornehag CG, Breeze E, et al. Factors associated with remission of eczema in children: a population-based follow-up study. Acta Derm Venereol. 2014;94(2):179-184. doi: https://doi.org/10.2340/00015555-1681von Kobyletzki LB, Bornehag CG, Breeze E, et al. Factors associated with remission of eczema in children: a population-based follow-up study. Acta Derm Venereol. 2014;94(2):179-184. doi: https://doi.org/10.2340/00015555-1681Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis. Dermatol Clin. 2017;35(3):291-297. doi: https://doi.org/10.1016/j.det.2017.02.003Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis. Dermatol Clin. 2017;35(3):291-297. doi: https://doi.org/10.1016/j.det.2017.02.003Nissen SP, Kjaer HF, Host A, et al. The natural course of sensitization and allergic diseases from childhood to adulthood. Pediatr Allergy Immunol. 2013;24(6):549-555. doi: https://doi.org/10.1111/pai.12108Nissen SP, Kjaer HF, Host A, et al. The natural course of sensitization and allergic diseases from childhood to adulthood. Pediatr Allergy Immunol. 2013;24(6):549-555. doi: https://doi.org/10.1111/pai.12108Luger T, Augustin M, Lambert J, et al. Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus. Pediatr Allergy Immunol. 2021;32(3):414-424. doi: https://doi.org/10.1111/pai.13422Luger T, Augustin M, Lambert J, et al. Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus. Pediatr Allergy Immunol. 2021;32(3):414-424. doi: https://doi.org/10.1111/pai.13422Wollenberg A, Werfel T, Ring J, et al. Atopic Dermatitis in Children and Adults — Diagnosis and Treatment. Dtsch Arztebl Int. 2023;120(13):224-234. doi: https://doi.org/10.3238/arztebl.m2023.0011Wollenberg A, Werfel T, Ring J, et al. Atopic Dermatitis in Children and Adults — Diagnosis and Treatment. Dtsch Arztebl Int. 2023;120(13):224-234. doi: https://doi.org/10.3238/arztebl.m2023.0011Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol. 2012;129(5):1187-1197. doi: https://doi.org/10.1016/j.jaci.2012.02.036Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol. 2012;129(5):1187-1197. doi: https://doi.org/10.1016/j.jaci.2012.02.036Hui-Beckman JW, Goleva E, Berdyshev E, Leung DYM. Endotypes of atopic dermatitis and food allergy. J Allergy Clin Immunol. 2023; 151(1):26-28. doi: https://doi.org/10.1016/j.jaci.2022.07.021Hui-Beckman JW, Goleva E, Berdyshev E, Leung DYM. Endotypes of atopic dermatitis and food allergy. J Allergy Clin Immunol. 2023; 151(1):26-28. doi: https://doi.org/10.1016/j.jaci.2022.07.021Flohr C, Perkin M, Logan K, et al. Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants. J Invest Dermatol. 2014;134(2):345-350. doi: https://doi.org/10.1038/jid.2013.298Flohr C, Perkin M, Logan K, et al. Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants. J Invest Dermatol. 2014;134(2):345-350. doi: https://doi.org/10.1038/jid.2013.298Spergel JM, Boguniewicz M, Schneider L, et al. Food allergy in infants with atopic dermatitis: limitations of food-specific IgE measurements. Pediatrics. 2015;136(6):e1530-e1538. doi: https://doi.org/10.1542/peds.2015-1444Spergel JM, Boguniewicz M, Schneider L, et al. Food allergy in infants with atopic dermatitis: limitations of food-specific IgE measurements. Pediatrics. 2015;136(6):e1530-e1538. doi: https://doi.org/10.1542/peds.2015-1444Roduit C, Frei R, Depner M, et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017;171(7):655-662. doi: https://doi.org/10.1001/jamapediatrics.2017.0556Roduit C, Frei R, Depner M, et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017;171(7):655-662. doi: https://doi.org/10.1001/jamapediatrics.2017.0556Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. doi: https://doi.org/10.1016/j.jaad.2009.11.011Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. doi: https://doi.org/10.1016/j.jaad.2009.11.011Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4): 818-823. doi: https://doi.org/10.1016/j.jaci.2014.08.005Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4): 818-823. doi: https://doi.org/10.1016/j.jaci.2014.08.005Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824-830.e6. doi: https://doi.org/10.1016/j.jaci.2014.07.060Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824-830.e6. doi: https://doi.org/10.1016/j.jaci.2014.07.060Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet. 2020;395(10228):962-972. doi: https://doi.org/10.1016/S0140-6736(19)32984-8Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet. 2020;395(10228):962-972. doi: https://doi.org/10.1016/S0140-6736(19)32984-8Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2020;395(10228):951-961. doi: https://doi.org/10.1016/S0140-6736(19)32983-6Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2020;395(10228):951-961. doi: https://doi.org/10.1016/S0140-6736(19)32983-6Paller AS, Spergel JM, Mina-Osorio P, et al. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46-55. doi: https://doi.org/10.1016/j.jaci.2018.11.006Paller AS, Spergel JM, Mina-Osorio P, et al. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46-55. doi: https://doi.org/10.1016/j.jaci.2018.11.006Schneider L, Hanifin J, Boguniewicz M, et al. Study of the Atopic March: Development of Atopic Comorbidities. Pediatr Dermatol. 2016;33(4):388-398. doi: https://doi.org/10.1111/pde.12867Schneider L, Hanifin J, Boguniewicz M, et al. Study of the Atopic March: Development of Atopic Comorbidities. Pediatr Dermatol. 2016;33(4):388-398. doi: https://doi.org/10.1111/pde.12867Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475-1482. doi: https://doi.org/10.1111/all.12049Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475-1482. doi: https://doi.org/10.1111/all.12049Wan J, Mitra N, Hoffstad OJ, et al. Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: A cohort study. J Am Acad Dermatol. 2017;77(4): 634-640. doi: https://doi.org/10.1016/j.jaad.2017.06.013Wan J, Mitra N, Hoffstad OJ, et al. Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: A cohort study. J Am Acad Dermatol. 2017;77(4): 634-640. doi: https://doi.org/10.1016/j.jaad.2017.06.013Gough H, Grabenhenrich L, Reich A, et al. Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. Pediatr Allergy Immunol. 2015;26(5):431-437. doi: https://doi.org/10.1111/pai.12410Gough H, Grabenhenrich L, Reich A, et al. Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. Pediatr Allergy Immunol. 2015;26(5):431-437. doi: https://doi.org/10.1111/pai.12410Grabenhenrich LB, Keil T, Reich A, et al. Prediction and prevention of allergic rhinitis: a birth cohort study of 20 years. J Allergy Clin Immunol. 2015;136(4):932-940.e12. doi: https://doi.org/10.1016/j.jaci.2015.03.040Grabenhenrich LB, Keil T, Reich A, et al. Prediction and prevention of allergic rhinitis: a birth cohort study of 20 years. J Allergy Clin Immunol. 2015;136(4):932-940.e12. doi: https://doi.org/10.1016/j.jaci.2015.03.040Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25. doi: https://doi.org/10.1016/j.jid.2016.08.022Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25. doi: https://doi.org/10.1016/j.jid.2016.08.022Schmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy. 2010;65(12):1506-1524. doi: https://doi.org/10.1111/j.1398-9995.2010.02449.xSchmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy. 2010;65(12):1506-1524. doi: https://doi.org/10.1111/j.1398-9995.2010.02449.xIvert LU, Wahlgren CF, Lindelof B, et al. Association between atopic dermatitis and autoimmune diseases: a population-based case-control study. Br J Dermatol. 2021;185(2):335-342. doi: https://doi.org/10.1111/bjd.19624Ivert LU, Wahlgren CF, Lindelof B, et al. Association between atopic dermatitis and autoimmune diseases: a population-based case-control study. Br J Dermatol. 2021;185(2):335-342. doi: https://doi.org/10.1111/bjd.19624Paller A, Jaworski JC, Simpson EL, et al. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018;19(6):821-838. doi: https://doi.org/10.1007/s40257-018-0383-4Paller A, Jaworski JC, Simpson EL, et al. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018;19(6):821-838. doi: https://doi.org/10.1007/s40257-018-0383-4Acharya P, Mathur M. Association of atopic dermatitis with vitiligo: A systematic review and meta-analysis. J Cosmet Dermatol. 2020;19(8):2016-2020. doi: https://doi.org/10.1111/jocd.13263Acharya P, Mathur M. Association of atopic dermatitis with vitiligo: A systematic review and meta-analysis. J Cosmet Dermatol. 2020;19(8):2016-2020. doi: https://doi.org/10.1111/jocd.13263Ariens LFM, van Nimwegen KJM, Shams M, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol. 2019;99(9):762-768. doi: https://doi.org/10.2340/00015555-3212Ariens LFM, van Nimwegen KJM, Shams M, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol. 2019;99(9):762-768. doi: https://doi.org/10.2340/00015555-3212Eckert L, Gupta S, Gadkari A, et al. Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019;81(1):187-195. doi: https://doi.org/10.1016/j.jaad.2019.03.037Eckert L, Gupta S, Gadkari A, et al. Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019;81(1):187-195. doi: https://doi.org/10.1016/j.jaad.2019.03.037Chamlin SL, Chren MM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):281-288. doi: https://doi.org/10.1016/j.iac.2010.05.004Chamlin SL, Chren MM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):281-288. doi: https://doi.org/10.1016/j.iac.2010.05.004Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. doi: https://doi.org/10.1038/jid.2014.530Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. doi: https://doi.org/10.1038/jid.2014.530Balieva F, Kupfer J, Lien L, et al. The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries. Br J Dermatol. 2017;176(5):1170-1178. doi: https://doi.org/10.1111/bjd.15280Balieva F, Kupfer J, Lien L, et al. The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries. Br J Dermatol. 2017;176(5):1170-1178. doi: https://doi.org/10.1111/bjd.15280Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi: https://doi.org/10.1111/jdv.14891Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi: https://doi.org/10.1111/jdv.14891Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: https://doi.org/10.1111/jdv.14888Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: https://doi.org/10.1111/jdv.14888Giam YC, Hebert AA, Dizon MV, et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016;6(2): 120-128. doi: https://doi.org/10.5415/apallergy.2016.6.2.120Giam YC, Hebert AA, Dizon MV, et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016;6(2): 120-128. doi: https://doi.org/10.5415/apallergy.2016.6.2.120Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10(7):744-749.Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10(7):744-749.Lindh JD, Bradley M. Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review. Am J Clin Dermatol. 2015;16(5):341-359. doi: https://doi.org/10.1007/s40257-015-0146-4Lindh JD, Bradley M. Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review. Am J Clin Dermatol. 2015;16(5):341-359. doi: https://doi.org/10.1007/s40257-015-0146-4Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744. doi: https://doi.org/10.1111/jdv.16892Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744. doi: https://doi.org/10.1111/jdv.16892Coureau B, Bussieres JF, Tremblay S. Cushing's syndrome induced by misuse of moderate- to high-potency topical corticosteroids. Ann Pharmacother. 2008;42(12):1903-1907. doi: https://doi.org/10.1345/aph.1L067Coureau B, Bussieres JF, Tremblay S. Cushing's syndrome induced by misuse of moderate- to high-potency topical corticosteroids. Ann Pharmacother. 2008;42(12):1903-1907. doi: https://doi.org/10.1345/aph.1L067Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56: 211-216. doi: https://doi.org/10.1016/j.jaad.2006.05.073Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56: 211-216. doi: https://doi.org/10.1016/j.jaad.2006.05.073Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis. A systematic review. JAMA Dermatol. 2017;153(10):1036-1042. doi: https://doi.org/10.1001/jamadermatol.2017.2437Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis. A systematic review. JAMA Dermatol. 2017;153(10):1036-1042. doi: https://doi.org/10.1001/jamadermatol.2017.2437Bos B, Antonescu I, Osinga H, et al. Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers. Pediatr Dermatol. 2019;36(1): 100-104. doi: https://doi.org/10.1111/pde.13698Bos B, Antonescu I, Osinga H, et al. Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers. Pediatr Dermatol. 2019;36(1): 100-104. doi: https://doi.org/10.1111/pde.13698Mueller SM, Itin P, Vogt DR, et al. Assessment of “corticophobia” as an indicator of non-adherence to topical corticosteroids: a pilot study. J Dermatolog Treat. 2017;28(2):104-111. doi: https://doi.org/10.1080/09546634.2016.1201189Mueller SM, Itin P, Vogt DR, et al. Assessment of “corticophobia” as an indicator of non-adherence to topical corticosteroids: a pilot study. J Dermatolog Treat. 2017;28(2):104-111. doi: https://doi.org/10.1080/09546634.2016.1201189Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333-343. doi: https://doi.org/10.1159/000484407Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333-343. doi: https://doi.org/10.1159/000484407Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30(3):165-169. doi: https://doi.org/10.5114/pdia.2013.35619Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30(3):165-169. doi: https://doi.org/10.5114/pdia.2013.35619Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus — an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13(12):721-730. doi: https://doi.org/10.1111/j.0906-6705.2004.00269.xGrassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus — an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13(12):721-730. doi: https://doi.org/10.1111/j.0906-6705.2004.00269.xJensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;124(3 Suppl 2): R19-R28. doi: https://doi.org/10.1016/j.jaci.2009.07.015Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;124(3 Suppl 2): R19-R28. doi: https://doi.org/10.1016/j.jaci.2009.07.015Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142(2):155-162. doi: https://doi.org/10.1067/mpd.2003.65Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142(2):155-162. doi: https://doi.org/10.1067/mpd.2003.65Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. doi: https://doi.org/10.1542/peds.2014-1990Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. doi: https://doi.org/10.1542/peds.2014-1990Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110(2): 277-284. doi: https://doi.org/10.1067/mai.2002.126500Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110(2): 277-284. doi: https://doi.org/10.1067/mai.2002.126500Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121-131. doi: https://doi.org/10.2165/00128071-200607020-00005Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121-131. doi: https://doi.org/10.2165/00128071-200607020-00005Luger T, Paller AS, Irvine AD, et al. Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol. 2021;35(7):1505-1518. doi: https://doi.org/10.1111/jdv.17272Luger T, Paller AS, Irvine AD, et al. Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol. 2021;35(7):1505-1518. doi: https://doi.org/10.1111/jdv.17272Papp KA, Werfel T, Fölster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005;52(2): 240-246. doi: https://doi.org/10.1016/j.jaad.2004.09.016Papp KA, Werfel T, Fölster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005;52(2): 240-246. doi: https://doi.org/10.1016/j.jaad.2004.09.016van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565-569. doi: https://doi.org/10.1016/j.jaci.2007.05.042van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565-569. doi: https://doi.org/10.1016/j.jaci.2007.05.042Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68-73. doi: https://doi.org/10.1016/j.jaad.2007.06.041Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68-73. doi: https://doi.org/10.1016/j.jaad.2007.06.041Sher LG, Chang J, Patel IB, et al. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012;92(5): 455-461. doi: https://doi.org/10.2340/00015555-1360Sher LG, Chang J, Patel IB, et al. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012;92(5): 455-461. doi: https://doi.org/10.2340/00015555-1360Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007;79(1):65-72.Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007;79(1):65-72.Sunderkötter C, Weiss JM, Bextermöller R, et al. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges. 2006;4(4):301-306. doi: https://doi.org/10.1111/j.1610-0387.2006.05932.xSunderkötter C, Weiss JM, Bextermöller R, et al. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges. 2006;4(4):301-306. doi: https://doi.org/10.1111/j.1610-0387.2006.05932.xStaab D, Kaufmann R, Brautigam M, Wahn U. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents‘ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005;16(6):527-533. doi: https://doi.org/10.1111/j.1399-3038.2005.00306.xStaab D, Kaufmann R, Brautigam M, Wahn U. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents‘ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005;16(6):527-533. doi: https://doi.org/10.1111/j.1399-3038.2005.00306.xGollnick H, Luger T, Freytag S, Brautigam M. StabiEL: stabilization of skin condition with Elidel — a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. J Eur Acad Dermatol Venereol. 2008;22(11):1319-1325. doi: https://doi.org/10.1111/j.1468-3083.2008.02807.xGollnick H, Luger T, Freytag S, Brautigam M. StabiEL: stabilization of skin condition with Elidel — a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. J Eur Acad Dermatol Venereol. 2008;22(11):1319-1325. doi: https://doi.org/10.1111/j.1468-3083.2008.02807.x

The authors declare that there are no conflicts of interest present.